Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TG Therapeutics Inc (TGTX) vs Visa Inc (V) Price & Performance

TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

TG Therapeutics Inc vs Visa Inc — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Visa Inc trades at $359.7 (market cap $671.74B). The key difference: Visa Inc is far larger — about 87.9× TG Therapeutics Inc's market cap, and Visa Inc pays a 0.74% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.

TGTXV
Market Cap
$7.64B$671.74B
Sector
HealthFinancials
52-Week High
$59.06$370.47
52-Week Low
$26.94$295.52
Enterprise Value
$7.84B$682.32B
Volume
10,431,336
Dividend Yield
0.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.

Visa Inc

Visa (V) trades at $360.00, down 0.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.32, and maintains robust fundamentals including a 50.78% net income margin and $20.06B net income for 2025. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for growth in digital payments.

The outlook for Visa remains positive with an 85% analyst buy rating and a $426.31 consensus price target, implying 18% upside. Key risks include competitive pressures from fintech and regulatory scrutiny, but sustained revenue growth and high profitability support long-term investor appeal. The stock's valuation at a P/E of 30.88 reflects premium pricing justified by its market leadership.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX

About Visa Inc

Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.

Read more on V